- Home
- BH vs COGT Comparison
BH vs COGT Comparison
Compare BH & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- COGT
- Stock Information
- Founded
- BH 1934
- COGT 2014
- Country
- BH United States
- COGT United States
- Employees
- BH N/A
- COGT N/A
- Industry
- BH Restaurants
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- BH Consumer Discretionary
- COGT Health Care
- Exchange
- BH Nasdaq
- COGT Nasdaq
- Market Cap
- BH 904.4M
- COGT 1.1B
- IPO Year
- BH N/A
- COGT 2018
- Fundamental
- Price
- BH $341.90
- COGT $15.37
- Analyst Decision
- BH
- COGT Strong Buy
- Analyst Count
- BH 0
- COGT 11
- Target Price
- BH N/A
- COGT $21.20
- AVG Volume (30 Days)
- BH 14.0K
- COGT 2.1M
- Earning Date
- BH 11-07-2025
- COGT 11-11-2025
- Dividend Yield
- BH N/A
- COGT N/A
- EPS Growth
- BH N/A
- COGT N/A
- EPS
- BH 146.55
- COGT N/A
- Revenue
- BH $377,176,000.00
- COGT N/A
- Revenue This Year
- BH N/A
- COGT N/A
- Revenue Next Year
- BH N/A
- COGT N/A
- P/E Ratio
- BH $25.68
- COGT N/A
- Revenue Growth
- BH 4.14
- COGT N/A
- 52 Week Low
- BH $165.36
- COGT $3.72
- 52 Week High
- BH $336.63
- COGT $16.22
- Technical
- Relative Strength Index (RSI)
- BH 73.77
- COGT 68.59
- Support Level
- BH $314.59
- COGT $13.72
- Resistance Level
- BH $332.90
- COGT $16.22
- Average True Range (ATR)
- BH 9.69
- COGT 0.69
- MACD
- BH 1.91
- COGT 0.23
- Stochastic Oscillator
- BH 95.91
- COGT 80.13
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.